

Daniel James Hodson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/586343/publications.pdf>

Version: 2024-02-01

33
papers

3,667
citations

394421

19
h-index

377865

34
g-index

36
all docs

36
docs citations

36
times ranked

5811
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1396-1407.	27.0	1,443
2	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012, 490, 116-120.	27.8	759
3	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. <i>Blood</i> , 2020, 135, 1759-1771.	1.4	271
4	Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia. <i>Nature Immunology</i> , 2010, 11, 717-724.	14.5	187
5	RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence. <i>Science</i> , 2016, 352, 453-459.	12.6	142
6	Umbralisib, a Dual PI3K β /CK1 δ Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1609-1618.	1.6	111
7	Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E2039-46.	7.1	81
8	Non-Hodgkin lymphoma. <i>BMJ: British Medical Journal</i> , 2018, 362, k3204.	2.3	60
9	Maintenance of the marginal-zone B cell compartment specifically requires the RNA-binding protein ZFP36L1. <i>Nature Immunology</i> , 2017, 18, 683-693.	14.5	59
10	Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7260-E7267.	7.1	53
11	RNA-binding proteins in hematopoiesis and hematological malignancy. <i>Blood</i> , 2019, 133, 2365-2373.	1.4	52
12	Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2018, 9, 3839.	12.8	51
13	Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?. <i>British Journal of Haematology</i> , 2022, 196, 814-829.	2.5	51
14	Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. <i>Molecular Cell</i> , 2021, 81, 4059-4075.e11.	9.7	42
15	Challenging perspectives on the cellular origins of lymphoma. <i>Open Biology</i> , 2016, 6, 160232.	3.6	40
16	Genetic modification of primary human B cells to model high-grade lymphoma. <i>Nature Communications</i> , 2019, 10, 4543.	12.8	36
17	Application of the LymphGen classification tool to 928 clinically and genetically characterised cases of diffuse large B cell lymphoma (DLBCL). <i>British Journal of Haematology</i> , 2021, 192, 216-220.	2.5	28
18	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. <i>Blood</i> , 2022, 139, 538-553.	1.4	27

#	ARTICLE	IF	CITATIONS
19	Targeting MEK in vemurafenib-resistant hairy cell leukemia. <i>Leukemia</i> , 2019, 33, 541-545.	7.2	26
20	PI3K γ inhibition reshapes follicular lymphoma's immune microenvironment cross talk and unleashes the activity of venetoclax. <i>Blood Advances</i> , 2020, 4, 4217-4231.	5.2	23
21	Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 14421-14432.	7.1	17
22	THE ROLE OF PI3K SIGNALLING IN THE B CELL RESPONSE TO ANTIGEN. <i>Advances in Experimental Medicine and Biology</i> , 2009, 633, 43-53.	1.6	16
23	An Emerging Role of RNA-Binding Proteins as Multifunctional Regulators of Lymphocyte Development and Function. <i>Advances in Immunology</i> , 2012, 115, 161-185.	2.2	15
24	Genetic manipulation and immortalized culture of ex vivo primary human germinal center B cells. <i>Nature Protocols</i> , 2021, 16, 2499-2519.	12.0	15
25	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2108-2113.	7.2	13
26	Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network. <i>Blood Advances</i> , 2022, 6, 5716-5731.	5.2	12
27	DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes. <i>Molecular Cancer</i> , 2021, 20, 134.	19.2	9
28	<i>SGK1</i> mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence. <i>Blood</i> , 2021, 138, 959-964.	1.4	8
29	Umbralisib, the Once Daily Dual Inhibitor of PI3K γ and Casein Kinase-1 μ Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial. <i>Blood</i> , 2020, 136, 34-35.	1.4	8
30	Acquired CARD11 Mutation Promotes BCR Independence in Diffuse Large B Cell Lymphoma. <i>JCO Precision Oncology</i> , 2021, 5, 145-152.	3.0	4
31	Life History of Normal Human Lymphocytes Revealed By Somatic Mutations. <i>Blood</i> , 2019, 134, 1045-1045.	1.4	2
32	Diffuse large B-cell lymphoma genetics "simplifying the subtyping. <i>British Journal of Haematology</i> , 2021, 195, 651-652.	2.5	1
33	Early Loss of CREBBP Confers Malignant Stem Cell Properties on Lymphoid Progenitors. <i>Blood</i> , 2016, 128, 460-460.	1.4	1